California is currently home to 5954 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Recruiting
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: First Oc Dermatology, Fountain Valley, California
Conditions: Atopic Dermatitis
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/02/2024
Locations: Clinical Study Site, Lancaster, California
Conditions: Inflammatory Bowel Diseases, Crohn's Disease
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Investigative Site US315, Laguna Niguel, California
Conditions: Hidradenitis Suppurativa (HS)
MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI
Recruiting
This study aims to test the feasibility and acceptability of a brief behavioral intervention that combines two treatments, Motivational Interviewing (MI) and Cognitive Behavioral Therapy (CBT), that have been shown to work in prior research studies. The format of the intervention will be a combination of in-person sessions and remote elements delivered via mobile phone (together called MI-CBTech). The goal of the intervention is to improve community integration in Veterans with serious mental il... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2024
Locations: VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California
Conditions: Psychotic Affective Disorders, Psychotic Mood Disorders, Homelessness, Ill-Housed Persons, Schizophrenia Spectrum Disorders
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Recruiting
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2024
Locations: University of California Irvine, Orange, California
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Tien Q Nguyen Md Inc, Fountain Valley, California
Conditions: NonSegmental Vitiligo
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: University of California Irvine, Irvine, California
Conditions: NonSegmental Vitiligo
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Recruiting
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Pacific Cancer Medical Center, Anaheim, California
Conditions: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Recruiting
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A*11:01. The purpose of this study is to find the best dose of AFNT-211 th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: USC Norris Comprehensive, Los Angeles, California
Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
Recruiting
The goal of this clinical study is to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for prevention of HIV in the cisgender women in the US. The primary objectives of this study are: 1) to characterize the pharmacokinetics (PK) of LEN in United States (US) cisgender women; 2) to evaluate the safety of LEN and F/TDF for pre-exposure prophylaxis (PrEP) in US cisgender women; and 3) to evaluate the gener... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: UCSD Antiviral Research Center (AVRC), San Diego, California
Conditions: Pre-Exposure Prophylaxis of HIV Infection
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
Recruiting
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
05/02/2024
Locations: Pd0060 50519, Fountain Valley, California
Conditions: Parkinson Disease
Study of ALE.C04 in Patients With Head and Neck Cancer
Recruiting
The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and as monotherapy and to assess anti-tumor activity of ALE.C04 monotherapy and in combination with pembrolizumab in patients with Head and Neck Cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: University of Southern California USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma